Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IR · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 50 mg oral suspension | EXPERIMENTAL | once daily for one day |
| 50 mg CR Type 1 | EXPERIMENTAL | once daily for one day |
| 50 mg CR Type 2 | EXPERIMENTAL | once daily for one day |
| 50 mg SR Type 3 | EXPERIMENTAL | once daily for one day |
| Name | Type | Description |
|---|---|---|
| suspension IR | DRUG | 50 mg IR suspension once daily for one day |
| CR 1 | DRUG | 50 mg shorter release CR once daily for one day |
| CR 2 | DRUG | 50 mg medium release CR once daily for one day |
| CR 3 | DRUG | longer release SR formulation once daily for one day |
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG ...
Top 20 of 28 competitors
IR is an investigational small molecule being developed for rheumatoid arthritis. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied for its potential to treat this autoimmune condition.
IR is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical research on this investigational drug for rheumatoid arthritis.
IR is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of rheumatoid arthritis, with one completed Phase 1 trial.
IR has one completed Phase 1 clinical trial registered as NCT00782600. This study evaluated controlled release formulations of CE-224,535 against the immediate release formulation in normal volunteers. The trial enrolled 16 participants in the United States and was completed.
IR is associated with the compound CE-224,535, as indicated in the clinical trial title. The study compared controlled release formulations of CE-224,535 against the immediate release formulation, suggesting IR may be a formulation or identifier for this compound.